BioCryst Pharmaceuticals Says Drug Shows Evidence of Reducing Attacks Among Hereditary Angioedema Patients
BioCryst Pharmaceuticals Says Drug Shows Evidence of Reducing Attacks Among Hereditary Angioedema Patients
BioCryst Pharmicals表示，藥物顯示出減少遺傳性血管性水腫患者發作的證據
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊